GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Duopharma Biotech Bhd (XKLS:7148) » Definitions » Capex-to-Operating-Cash-Flow

Duopharma Biotech Bhd (XKLS:7148) Capex-to-Operating-Cash-Flow : 0.23 (As of Mar. 2025)


View and export this data going back to 2002. Start your Free Trial

What is Duopharma Biotech Bhd Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Duopharma Biotech Bhd's Capital Expenditure for the three months ended in Mar. 2025 was RM-7.27 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was RM31.31 Mil.

Hence, Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2025 was 0.23.


Duopharma Biotech Bhd Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Duopharma Biotech Bhd Capex-to-Operating-Cash-Flow Chart

Duopharma Biotech Bhd Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 2.66 1.01 0.81 0.41

Duopharma Biotech Bhd Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.13 - 0.11 0.53 0.23

Competitive Comparison of Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow falls into.


;
;

Duopharma Biotech Bhd Capex-to-Operating-Cash-Flow Calculation

Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-33.892) / 83.343
=0.41

Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-7.268) / 31.305
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Duopharma Biotech Bhd  (XKLS:7148) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Duopharma Biotech Bhd Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Duopharma Biotech Bhd's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Duopharma Biotech Bhd Business Description

Traded in Other Exchanges
N/A
Address
Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.

Duopharma Biotech Bhd Headlines

No Headlines